Welcome to our dedicated page for Dianthus Therapeutics /DE/ SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Dianthus Therapeutics /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Dianthus Therapeutics /DE/'s regulatory disclosures and financial reporting.
Dianthus Therapeutics, Inc. (DNTH) executive Simrat Randhawa, EVP and Head of R&D, reported an exercise-and-sell transaction on September 1, 2026. Randhawa exercised stock options for 23,124 shares of common stock at exercise prices of $17.88, $21.77, and $22.07 per share, then sold 23,124 shares of common stock in multiple open-market transactions at weighted average prices around $105–$107 per share. The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on August 14, 2025. The options exercised relate to awards that vest in equal monthly installments over four years beginning January 1, 2024, May 1, 2024, and January 1, 2025, respectively.
Dianthus Therapeutics, Inc. (DNTH) is the issuer for a notice filed by officer Simrat Randhawa under Rule 144 to potentially sell up to 23,124 shares of common stock through Morgan Stanley Smith Barney LLC on or after 09/01/2026 on NASDAQ. The shares are to be acquired via exercise of stock options for cash from the issuer. The notice lists an aggregate market value of $2,442,125.64 for the securities covered and indicates 55,934,378 shares of common stock outstanding.
Dianthus Therapeutics, Inc. (DNTH) director Simon Read reported an option exercise-and-sale on common stock. He exercised 2,778 stock options at an exercise price of $18.36 per share, acquiring 2,778 shares of common stock, and on the same date sold 2,778 shares at a weighted-average price of $117.55 per share. The option exercise left 19,445 options reported as outstanding after the transaction, with the option expiring on May 22, 2035. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026, and the option award vests in three equal annual installments, subject to continued service.
Dianthus Therapeutics, Inc. insider activity: Adam M. Veness, SVP, General Counsel and Secretary, reported exercising stock options for 15,000 shares of common stock on August 13, 2026 at an exercise price of $18.17 per share. This converted a stock option into directly held common shares.
The derivative position of 15,000 option shares was disposed of upon exercise, leaving Veness with 73,240 derivative securities reported following the transaction. The option award vested 25% on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to his continued service.
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of 1,696,751 shares of Dianthus Therapeutics, Inc. common stock, including 510,400 shares issuable upon exercise of call options. This represents 3.1% of the company’s 54,666,233 shares outstanding as of May 1, 2026.
The reporting persons have shared voting and dispositive power over all reported shares and no sole voting or dispositive power. The filing is an amendment to a Schedule 13G and confirms ownership of less than 5% of the class.
Dianthus Therapeutics, Inc. has a significant shareholder group led by Wellington Management entities, which report passive beneficial ownership of its common stock. Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP and Wellington Management Company LLP collectively report beneficial ownership of 3,229,882 shares of common stock, representing approximately 5.9–5.91% of the class.
These shares are held of record by clients of various Wellington investment advisers. The Wellington filers report 0 shares with sole voting or dispositive power, and only shared voting and dispositive power over the reported shares. No individual client is reported to have rights over more than five percent of the class.
Dianthus Therapeutics, Inc. director Anne McGeorge reported option exercises and related sales of common stock. On August 10, 2026, she exercised options for 7,750 shares of common stock at exercise prices of $19.36 and $11.20 per share, then sold 7,750 shares in multiple transactions at weighted average prices between $106.79 and $111.63 per share. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
Dianthus Therapeutics (DNTH) director Simon Read exercised stock options for 2,777 shares of common stock at an exercise price of $18.36 per share, converting a Stock Option (Right to Buy) into common shares. On the same date, he reported six open-market sales totaling 2,777 shares at per-share prices including $107.11, $108.17, $108.95, $109.96, $111.05 and $111.77, each disclosed as a weighted average price across multiple trades within specified ranges. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026. Following the option exercise, Read reported 22,223 option shares remaining under the same award, which vests in three equal annual installments, subject to continued service and an expiration date of May 22, 2035.
Dianthus Therapeutics executive Adam M. Veness, SVP, General Counsel and Secretary, exercised 20,000 stock options at an exercise price of $17.88 per share and sold the same number of common shares in open-market transactions at prices around $110–$111 per share. The trades on August 7 and 10, 2026 were effected under a Rule 10b5-1 trading plan adopted on March 18, 2026. The options exercised are from an award vesting in equal monthly installments over four years after January 1, 2024.
A shareholder associated with ticker DNTH filed to sell common stock under Rule 144. The filing lists 16,167 common shares with an aggregate market value of $1,760,909.64, to be transacted through Morgan Stanley Smith Barney LLC Executive Financial Services on 08/10/2026 on NASDAQ. The shares relate to an exercise of stock options for cash from the issuer on the same date. Over the prior three months, 10b5-1 plan sales by Adam M. Veness included 3,833 shares for $424,317.70 on 08/07/2026 and 30,000 shares for $2,424,033.00 on 06/17/2026.